The company remains in a pre-revenue phase, reporting nominal quarterly revenue of only $8,000 in 2025Q4 while maintaining high fixed R&D expenditures that frequently exceed $4.0M per quarter.
| Sales/Revenue | 8K | 8K | 8K | 170K | 11.07M | 0 | 0 | 0 |
| Revenue Growth % | - | 0% | -95.29% | -98.46% | - | - | - | - |
| Cost of Goods Sold | 292K | 574K | 903K | 1.02M | 968K | 895K | 658K | 0 |
| COGS % of Revenue | - | 7175% | 11287.5% | 598.82% | 8.75% | - | - | - |
| Gross Profit | -284K | -566K | -895K | -848K | 10.1M | -895K | -658K | 0 |
| Gross Margin % | -3550% | -7075% | -11187.5% | -498.82% | 91.25% | - | - | - |
| Gross Profit Growth % | - | 36.76% | -5.54% | -108.4% | 1228.49% | -36.02% | - | - |
| Operating Expenses | 33.48M | 32.65M | 30.8M | 23.32M | 13.11M | 13.72M | 11.76M | 10.87M |
| OpEx % of Revenue | - | 408100% | 385012.5% | 13715.88% | 118.48% | - | - | - |
| Selling, General & Admin | 13.37M | 13.37M | 12.71M | 11.57M | 5M | 8.29M | 6.2M | 3.34M |
| SG&A % of Revenue | - | 167137.5% | 158825% | 6804.71% | 45.2% | - | - | - |
| Research & Development | 20.4M | 19.85M | 19M | 12.77M | 9.08M | 6.32M | 6.23M | 7.53M |
| R&D % of Revenue | - | 248137.5% | 237475% | 7510% | 82.02% | - | - | - |
| Other Operating Expenses | -291K | -574K | -903K | -1.02M | -968K | -895K | -658K | 0 |
| Operating Income | -33.76M | -33.21M | -31.7M | -24.16M | -3.01M | -14.61M | -12.42M | -10.87M |
| Operating Margin % | -422037.5% | -415175% | -396200% | -14214.71% | -27.22% | - | - | - |
| Operating Income Growth % | - | -4.79% | -31.16% | -702.02% | 79.38% | -17.64% | -14.28% | - |
| EBITDA | -33.28M | -32.64M | -30.79M | -23.15M | -2.04M | -13.72M | -11.76M | -10.49M |
| EBITDA Margin % | -416037.5% | -408000% | -384912.5% | -13615.88% | -18.48% | - | - | - |
| EBITDA Growth % | -8.76% | -6% | -33.03% | -1031.88% | 85.09% | -16.61% | -12.1% | - |
| D&A (Non-Cash Add-back) | 480K | 574K | 903K | 1.02M | 968K | 895K | 658K | 376K |
| EBIT | -33.76M | -33.21M | -29.87M | -27.48M | -2.7M | -14.56M | -12.42M | -10.87M |
| Net Interest Income | 1.99M | 1.07M | 1.46M | -3.73M | -1.41M | -1.81M | -1.22M | -761K |
| Interest Income | 1.99M | 1.07M | 1.46M | 244K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 3.97M | 1.41M | 1.81M | 1.22M | 761K |
| Other Income/Expense | 1.99M | 1.07M | 1.83M | -4.13M | -1.09M | -1.76M | -1.22M | -761K |
| Pretax Income | -31.78M | -32.15M | -29.87M | -28.3M | -4.11M | -16.38M | -13.64M | -11.63M |
| Pretax Margin % | -397225% | -401812.5% | -373362.5% | -16645.29% | -37.11% | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 1.1M | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | -26.78% | 0% | 0% | 0% |
| Net Income | -31.78M | -32.15M | -29.87M | -28.3M | -5.21M | -17.8M | -14.86M | -11.63M |
| Net Margin % | -397225% | -401812.5% | -373362.5% | -16645.29% | -47.05% | - | - | - |
| Net Income Growth % | -7.68% | -7.62% | -5.56% | -443.44% | 70.74% | -19.72% | -27.8% | - |
| Net Income (Continuing) | -31.78M | -32.15M | -29.87M | -28.3M | -5.21M | -16.38M | -13.64M | -11.63M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.98 | -0.86 | -0.95 | -1.16 | -0.21 | -0.69 | -0.58 | -0.49 |
| EPS Growth % | 1.12% | 9.47% | 18.1% | -452.38% | 69.57% | -18.97% | -18.37% | - |
| EPS (Basic) | - | -0.86 | -0.95 | -1.16 | -0.21 | -0.69 | -0.58 | -0.49 |
| Diluted Shares Outstanding | 32.5M | 37.18M | 31.45M | 24.43M | 24.55M | 23.62M | 23.62M | 23.62M |
| Basic Shares Outstanding | 32.5M | 37.18M | 31.45M | 24.43M | 24.55M | 23.62M | 23.62M | 23.62M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Clinical Trial Funding Shortfall
As indicated by recent financial filings, GNLX remains a pre-commercial entity with nominal quarterly revenue, such as the $8,000 reported in 2025Q4, confirming that the company currently lacks any sustainable commercial operations or recurring revenue streams to support its ongoing research and development activities.
The absence of meaningful top-line growth is consistent with a clinical-stage biotechnology firm that has yet to secure regulatory approval for its lead candidate. Investors should interpret these figures as a reflection of the company's reliance on external capital rather than operational performance.
Based on reported quarterly data, GNLX consistently allocates the majority of its capital to R&D, with expenditures frequently exceeding $4.0M per quarter, which underscores the high fixed-cost burden required to maintain the OnPrime Phase 3 clinical trial and associated corporate infrastructure during this pre-revenue phase.
The company's cost structure is entirely decoupled from its revenue, creating a persistent structural deficit. This expense discipline appears focused exclusively on trial progression, leaving little room for operational flexibility should clinical timelines face unexpected regulatory or logistical delays.
According to recent income statements, GNLX consistently records significant stock-based compensation, reaching $2.3M in 2025Q3, which serves to dilute existing shareholders while providing a non-cash expense that obscures the true magnitude of the company's underlying cash burn required to sustain its current clinical development program.
The reliance on equity-based incentives suggests a strategy to preserve limited cash reserves, yet this practice complicates the assessment of true operational costs. Analysts should monitor the relationship between these non-cash charges and the actual cash used in operating activities to gauge the true runway.
With a reported cash balance of only $5.33M, as noted in recent disclosures, GNLX faces a precarious liquidity position that may necessitate immediate dilutive financing, potentially undermining the value of current equity if the company cannot secure a strategic partnership or non-dilutive funding in the near term.
The current cash position appears insufficient to support the ongoing Phase 3 trial through to completion, creating a binary risk for investors. This vulnerability suggests that the company's survival is contingent upon external capital market conditions rather than the intrinsic clinical progress of its lead candidate.
Quick answers to the most common questions about buying GNLX stock.
For fiscal year 2025, Genelux Corporation (GNLX) reported total revenue of $0.0M.
Genelux Corporation (GNLX) reported a net loss of $32.1M for the fiscal year ending 2025.
Genelux Corporation (GNLX) reported an operating income of $-33.2M, resulting in an operating profit margin of -415175.0%. This margin reflects the operational efficiency of the business before interest and taxes.
Genelux Corporation (GNLX) generated $-0.6M in gross profit for the year, representing a gross profit margin of -7075.0%. This demonstrates the company's core pricing power and production efficiency.